Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
StandardStandard
Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease. / Hughes, D.; Hughes, D.A.; Dubois, D.
Yn: Value in Health, Cyfrol 6, Rhif 6, 01.11.2003, t. 613.
Yn: Value in Health, Cyfrol 6, Rhif 6, 01.11.2003, t. 613.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
HarvardHarvard
Hughes, D, Hughes, DA & Dubois, D 2003, 'Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease', Value in Health, cyfrol. 6, rhif 6, tt. 613.
APA
Hughes, D., Hughes, D. A., & Dubois, D. (2003). Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease. Value in Health, 6(6), 613.
CBE
Hughes D, Hughes DA, Dubois D. 2003. Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease. Value in Health. 6(6):613.
MLA
Hughes, D., D.A. Hughes a D. Dubois. "Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease". Value in Health. 2003, 6(6). 613.
VancouverVancouver
Hughes D, Hughes DA, Dubois D. Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease. Value in Health. 2003 Tach 1;6(6):613.
Author
RIS
TY - JOUR
T1 - Cost-utility analysis of on demand rabeprazole and esomeprazole for symptomatic gastro oesophageal reflux disease
AU - Hughes, D.
AU - Hughes, D.A.
AU - Dubois, D.
PY - 2003/11/1
Y1 - 2003/11/1
M3 - Article
VL - 6
SP - 613
JO - Value in Health
JF - Value in Health
SN - 1524-4733
IS - 6
ER -